Comparing the therapeutic efficacy of topical minoxidil and finasteride with topical minoxidil and oral finasteride in androgenetic alopecia: a randomized trial

Priyam Bhaskar Rai, Pragya Khushwaha, Nitish Jain, Swati Gupta


Background: There is an increased interest in the development and use of topical finasteride for treating androgenic alopecia (AGA) due to growing evidence of side effects from oral finasteride. In this study we aimed to compare the treatment outcomes of topical 5% minoxidil with 0.1% finasteride and topical 5% minoxidil with oral 1 mg finasteride.

Methods: 50 patients of stage III and IV of Hamilton-Norwood scale were randomly assigned to either Group A receiving topical 5% minoxidil and oral finasteride 1 mg and Group B receiving topical 5% minoxidil and topical 0.1% finasteride. After taking uninterrupted treatment for 12 months, patients were assessed for hair regrowth and maintenance using global photography and trichoscopy and compared with baseline parameters. Patients in both the groups were assessed for any adverse effects as well.

Results: At baseline, patients in both the treatment groups were similar with respect to their age at the time of presentation, family history of hair loss and Hamilton Norwood scale. In group A, three discontinued treatment and of the rest 65% maintained a good hair density and reduced hairfall. In group B, five discontinued treatment, of the rest 83% patients demonstrated good improvement in hair density (p<0.05).

Conclusions: The results of this study strongly support the use of topical finasteride in combination with topical 5% minoxidil for AGA and this may obviate the need of taking long term oral finasteride.


Androgenic alopecia, Finasteride, Minoxidil, Outcomes

Full Text:



Norwood OT. Male pattern baldness: classification and incidence. Southern Med J. 1975;68(11):1359-65.

Paus R, Cotsarelis G. The biology of hair follicles. New England J Med. 1999;341(7):491-7.

Marubayashi A, Nakaya Y, Fukui K, Li M, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Investigative Dermatol. 2001;117(6):1594-600.

Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J. Finasteride in the treatment of men with androgenetic alopecia. J American Academy Dermatol. 1998;39(4):578-89.

Choudhry R, Hodgins MB, VanderKwast TH, et al. Localization of androgen receptors in human skin by immunohistochemistry: Implications for the hormonal regulation of hair growth, seba- ceous glands and sweat glands. J Endocrinol. 1992;133:467–75.

Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives Dermatol. 2010;146(10):1141-50.

Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55:367-79.

Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, Kim DW, Kim MB, Kim SJ, Kim HO, Sim WY. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Annals Dermatol. 2012;24(3):311-8.

Shapiro J, Otberg N. Hair Loss and Restoration. Second Edition. CRC Press; 2015: 39.

Choi GS, Kim JH, Oh SY, Park JM, Hong JS, Lee YS, et al. Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia. Ann Dermatol. 2016;28(4):444–50.

Sintov A, Serafimovich S, Gilhar A. New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. International J Pharmaceutics. 2000;194(1):125-34.

Hajheydari Z, Saidee M, Akbari J, Shokoohi L. Comparison of therapeutic effects of finasteride gel and tablet in treatment of Androgenic Alopecia. J Mazandaran University Med Sci. 2007;17(57):25-31.

Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatology Online J. 2015;6(1):17.

Traish AM. 5alpha-reductase in human physiology : an unfolding in story. Endocr Pract. 2012;18:965-75.

Traish AM, Hassani J, cruay AT, Zitzman M, Hansen ML, Adverse side-effects of 5alpha-reductase inhibitor therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872-84.

Irwig MS, Kolulula S. persistent sexual side-effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747-53.

Romer B, Gass P. finasteride induced depression: new insights into possible pathomechanisms. J Cosmet Dermatol. 2010;9:331-2.

Irwig MS. Persistent sexual side-effects of finasteride. Could they be permanent? J Sex Med. 2012;9:2927-32.

Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128.